Creative Financing Strategies for Biotech's Bear Market, Beyond the VC Round

About this episode

Baruch Harris discusses creative financing strategies for biotech companies in a challenging market.

"A lot of biotech companies die because they run out of runway. And they might have been successful if they had another six or 12 months." Baruch Harris , Chief Operating Officer at Pretzel Therapeutics, has spent over two decades navigating the business side of life sciences, from consulting and big pharma to early-stage biotech. With a PhD in biochemistry and deep experience in business development, investor relations, and corporate strategy, he has been key in guiding Pretzel from seed stage through a $72.5 million Series A and subsequent Series B financing. In this episode of the PharmaSource podcast, Baruch shares the strategic decisions and creative financing structures that have kept Pretzel advancing its first-in-class mitochondrial biology pipeline, including a lead program currently wrapping up Phase 1 for rare mitochondrial depletion syndrome and an early-stage obesity asset. From spinout strategies to non-dilutive funding and the company's recent acquisition of Rome Therapeutics, his insights offer a practical roadmap for biotech leaders navigating today's capital-constrained environment. Read more .

People in this episode

Guest: Baruch Harris

Topics covered

• biotech financing
• capital constraints
• business strategy
• investor relations
• life sciences

Keywords

• biotech
• financing
• investor relations
• capital
• life sciences
• business development
• Series A
• Series B

Mentioned in this episode

Organizations: Pretzel Therapeutics, Rome Therapeutics, Life Science Networks

Places: biotech

More episodes of PharmaSource Podcast

• How Sanofi Navigates Regulatory CMC Across Global Markets: Insights from Manda Pasarkar · June 11, 2026 · 31 min
• The Politics Behind the Pipeline: How MFN Pricing and Tariffs Are Reshaping Pharma's Global Strategy · June 8, 2026 · 18 min
• How to Build a Resilient Global Vaccine Supply Chain: From Crisis to Capability · June 4, 2026 · 46 min
• How Lonza Is Outgrowing the CDMO Market with Bioconjugation, AI, and Regionalization · May 31, 2026 · 29 min
• The Strategic Partnership Gap: Why CDMOs Are Meeting Pharma's Expectations Less Than Half the Time with Simon-Kucher · May 27, 2026 · 26 min
• Decarbonizing Pharma: Why Green Chemistry Must Lead the Sustainability Agenda · May 18, 2026 · 27 min